{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:19:19Z","timestamp":1787505559207,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.pathol.2022.01.010","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T08:30:33Z","timestamp":1651739433000},"page":"700-706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cytokeratin 5\/6 expression in pT1 bladder cancer predicts intravesical recurrence in patients treated with bacillus Calmette\u2013Gu\u00e9rin instillation"],"prefix":"10.1016","volume":"54","author":[{"given":"Yuuki","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-8357","authenticated-orcid":false,"given":"Taishi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Sassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4855-4366","authenticated-orcid":false,"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2022.01.010_bib1","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","article-title":"The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.pathol.2022.01.010_bib2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib3","first-page":"1021","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/iju.14210","article-title":"Clinical practice guidelines for bladder cancer 2019 edition by the Japanese urological association: revision working position paper","volume":"27","author":"Matsumoto","year":"2020","journal-title":"Int J Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2015.07.010","article-title":"Predicting response to intravesical bacillus Calmette-Guerin immunotherapy: are we moving forward?","volume":"69","author":"Zuiverloon","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib8","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A\u00a0molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2022.01.010_bib9","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2022.01.010_bib10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrurol.2014.129","article-title":"Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer","volume":"11","author":"Choi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sjodahl","year":"2017","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2022.01.010_bib12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2022.01.010_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A\u00a0consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","article-title":"Identification of differential tumor subtypes of T1 bladder cancer","volume":"78","author":"Robertson","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2022.01.010_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pathol.2022.01.010_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00428-010-1017-2","article-title":"Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer","volume":"458","author":"Gaisa","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2022.01.010_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.humpath.2019.07.002","article-title":"The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5\/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder","volume":"91","author":"Calvete","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2022.01.010_bib19","doi-asserted-by":"crossref","first-page":"151397","DOI":"10.1016\/j.anndiagpath.2019.08.001","article-title":"Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5\/6, 14 and 20","volume":"43","author":"Jangir","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.pathol.2022.01.010_bib20","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.eururo.2015.02.021","article-title":"A\u00a0molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma","volume":"68","author":"Patschan","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2022.01.010_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00428-017-2064-8","article-title":"In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival","volume":"470","author":"Breyer","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2022.01.010_bib23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00428-019-02593-x","article-title":"Predicting outcomes in non-muscle invasive (Ta\/T1) bladder cancer: the role of molecular grade based on luminal\/basal phenotype","volume":"475","author":"Rebola","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2022.01.010_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00428-019-02618-5","article-title":"Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder","volume":"475","author":"Rodriguez Pena","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2022.01.010_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder","volume":"54","author":"Babjuk","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: international consensus panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.pathol.2022.01.010_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/iju.14153","article-title":"Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: its definition and future therapeutic strategies","volume":"27","author":"Kikuchi","year":"2020","journal-title":"Int J Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib28","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2022.01.010_bib29","first-page":"964","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"Bohle","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib30","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11255-019-02183-5","article-title":"Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics","volume":"51","author":"Slusarczyk","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.pathol.2022.01.010_bib31","first-page":"195","article-title":"Risk factor assessment in high-risk, bacillus Calmette-Guerin-treated, non-muscle-invasive bladder cancer","volume":"9","author":"Holz","year":"2017","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.pathol.2022.01.010_bib32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.euf.2018.07.032","article-title":"Predicting response to intravesical therapy in non-muscle-invasive bladder cancer","volume":"4","author":"Alameddine","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.pathol.2022.01.010_bib33","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/ajag.12075","article-title":"Factors associated with refraining from buying prescribed medications among older people in Europe","volume":"33","author":"Stankunas","year":"2014","journal-title":"Australas J Ageing"},{"key":"10.1016\/j.pathol.2022.01.010_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2022.01.010_bib35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","article-title":"Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants","volume":"75","author":"Warrick","year":"2019","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"10.1016\/j.pathol.2022.01.010_bib36","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/modpathol.2009.1","article-title":"Staging and reporting of urothelial carcinoma of the urinary bladder","volume":"22","author":"Cheng","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.01.010_bib37","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00428-018-2354-9","article-title":"Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications","volume":"472","author":"Barth","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2022.01.010_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/PAI.0b013e3182351ed3","article-title":"Utility of cytokeratin 5\/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia","volume":"20","author":"Edgecombe","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.pathol.2022.01.010_bib39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00428-021-03054-0","article-title":"Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer","volume":"479","author":"Garczyk","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2022.01.010_bib40","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.3892\/or.2017.5902","article-title":"STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells","volume":"38","author":"Tsujita","year":"2017","journal-title":"Oncol Rep"},{"key":"10.1016\/j.pathol.2022.01.010_bib41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cmet.2017.10.005","article-title":"Advances in hypoxia-inducible factor biology","volume":"27","author":"Choudhry","year":"2018","journal-title":"Cell Metab"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522001246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522001246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:28:46Z","timestamp":1758472126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302522001246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0031302522001246"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2022.01.010","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokeratin 5\/6 expression in pT1 bladder cancer predicts intravesical recurrence in patients treated with bacillus Calmette\u2013Gu\u00e9rin instillation","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2022.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}